Suppr超能文献

肝移植与乙肝表面抗原阳性的坏死后肝硬化:充分的免疫预防及丁型病毒合并感染作为长期预后的重要决定因素

Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis.

作者信息

Lerut J P, Donataccio M, Ciccarelli O, Roggen F, Jamart J, Laterre P F, Cornu C, Mazza D, Hanique G, Rahier J, Geubel A P, Otte J B

机构信息

Department of Digestive Surgery, St-Luc University Hospital, Catholic University of Louvain Medical School, Brussels, Belgium.

出版信息

J Hepatol. 1999 Apr;30(4):706-14. doi: 10.1016/s0168-8278(99)80203-7.

Abstract

BACKGROUND/AIMS: The place of liver transplantation in hepatitis B viral (HBV)-related diseases remains controversial because of the high rate of reinfection. The aim of this study was to define the determinants of long-term prognosis after transplantation.

METHODS

Fifty-eight patients were transplanted during the period February 1984-September 1996. Six patients died during the early (< 3 months) posttransplant period from causes unrelated to HBV infection. All 52 long-term (> 3 months) survivors were evaluated in relation to the mode of presentation, viral replication at time of transplantation, absence of hepatocellular cancer at time of transplantation and use of adequate immunoprophylaxis (IP). Adequate immunoprophylaxis, defined as maintenance of anti-HBs levels over 100 mUI/ml, was introduced in December 1989. Intention-to-treat IP analysis compared patients transplanted before and after this date. The median follow-up was 74 months (range 4 to 131). Forty-seven patients (90%) had a minimal follow-up of 3 years.

RESULTS

Five-year actuarial survival rates of 58 patients and of 52 long-term survivors were 72 +/- 6% and 80 +/- 6%, respectively. Univariate analysis showed that delta co-infection (n = 25) significantly improved survival (p < 0.001) [96 +/- 4% vs 63 +/- 10% in HBV patients (n = 27) at 5 years] as did absence of hepatocellular cancer (n = 36) (p = 0.020) [89 +/- 5% vs 61 +/- 12% in 16 non-cancer patients]. IP, however, significantly influenced 5-year survival in the HBV-patient group (n = 17) (p = 0.001) [85 +/- 10% vs 30 +/- 14% in 10 patients without IP). Multivariate analysis selected delta co-infection (p = 0.002) and IP (p = 0.01) as the significant determinants of prognosis independently influencing survival. Uni- and multivariate analyses showed that survival without reinfection was significantly influenced by IP (p = 0.002) [73 +/- 8% (n = 31) versus 33 +/- 12% in 15 non-treated patients).

CONCLUSIONS

Delta virus co-infection and immunoprophylaxis are the most important prognostic factors after transplantation for postnecrotic HBsAg-positive cirrhosis. Transplantation can be proposed as a therapeutic tool only if life-long adequate adjuvant therapy can be achieved. Under this condition good results can even be obtained if there is viral replication at the time of transplantation.

摘要

背景/目的:由于再感染率高,肝移植在乙型肝炎病毒(HBV)相关疾病中的地位仍存在争议。本研究的目的是确定移植后长期预后的决定因素。

方法

1984年2月至1996年9月期间,58例患者接受了肝移植。6例患者在移植后早期(<3个月)因与HBV感染无关的原因死亡。对所有52例长期(>3个月)存活者进行了评估,内容包括临床表现方式、移植时的病毒复制情况、移植时无肝细胞癌以及是否采用了充分的免疫预防(IP)措施。充分的免疫预防定义为抗-HBs水平维持在100 mUI/ml以上,于1989年12月开始实施。意向性治疗IP分析比较了在此日期前后移植的患者。中位随访时间为74个月(范围4至131个月)。47例患者(90%)至少随访了3年。

结果

58例患者和52例长期存活者的5年实际生存率分别为72±6%和80±6%。单因素分析显示,δ病毒合并感染(n = 25)显著提高了生存率(p < 0.001)[5年时,HBV患者(n = 27)为63±10%,而δ病毒合并感染患者为96±4%],移植时无肝细胞癌(n = 36)也有同样效果(p = 0.020)[16例非癌症患者为61±12%,36例无肝细胞癌患者为89±5%]。然而,IP对HBV患者组(n = 17)的5年生存率有显著影响(p = 0.001)[10例未接受IP的患者为30±14%,17例接受IP治疗的患者为85±该文档为医学专业学术文献翻译任务,主要内容是关于肝移植治疗乙肝相关疾病的研究,探讨移植后长期预后的决定因素,包括患者资料、研究方法、结果分析及结论等方面。10%]。多因素分析选择δ病毒合并感染(p = 0.002)和IP(p = 0.01)作为独立影响生存的预后重要决定因素。单因素和多因素分析均显示未再感染的生存率受IP显著影响(p = 0.002)[31例接受治疗的患者为73±8%,15例未接受治疗的患者为33±12%]。

结论

δ病毒合并感染和免疫预防是坏死性HBsAg阳性肝硬化移植后最重要的预后因素。只有当能够实现终身充分的辅助治疗时,才可以将肝移植作为一种治疗手段。在这种情况下,即使移植时存在病毒复制,也能取得良好的效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验